SMMTSummit Therapeutics Inc.

Nasdaq summittxinc.com


$ 7.81 $ 0.04 (0.51 %)    

Thursday, 27-Jun-2024 11:00:26 EDT
QQQ $ 481.07 $ 1.08 (0.23 %)
DIA $ 392.08 $ 0.84 (0.21 %)
SPY $ 545.82 $ 0.31 (0.06 %)
TLT $ 93.56 $ 0.13 (0.14 %)
GLD $ 215.23 $ 2.65 (1.25 %)
$ 7.77
$ 7.77
$ 7.60 x 400
$ 10.00 x 1,200
$ 7.65 - $ 7.91
$ 1.52 - $ 11.25
2,156,347
na
5.45B
$ -0.16
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-20-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-09-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-09-2023 12-31-2022 10-K
7 11-09-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-11-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-17-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
15 11-16-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-summit-therapeutics-stock-is-trading-8-higher-monday

Based on data from a Phase III HARMONi-A clinical trial, sponsored by Akeso, that showed promising results for treating certain...

 stifel-maintains-buy-on-summit-therapeutics-raises-price-target-to-14

Stifel analyst Bradley Canino maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from $8 to ...

 summit-therapeutics-raised-200m-via-institutional-offering-of-222m-shares-at-9share-for-clinical-development-of-ivonescimab-to-expand-license-territories-for-ivonescimab

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that the Comp...

 summit-therapeutics-ivonescimab-in-combination-with-chemotherapy-approved-in-china-by-nmpa-for-2l-egfrm-nsclc-based-on-harmoni-a-clinical-trial-clinically-meaningful-efficacy-observed-in-overall-survival-towards-ivonescimab-plus-chemotherapy-shares-currently-halted

 Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Bene...

 citigroup-maintains-buy-on-summit-therapeutics-raises-price-target-to-13

Citigroup analyst Yigal Nochomovitz maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price target from ...

 summit-therapeutics-lung-cancer-therapy-ivonescimab-shows-improved-progression-free-survival-versus-mercks-multi-billion-keytruda-in-china-study

Summit Therapeutics shares dropped 27.3% to $7.94 in premarket trading Friday after a 272.1% surge on Thursday. The company ann...